Jeff Roix is a Venture Partner and portfolio CEO at o2h Ventures, a therapeutics seed fund in Cambridge UK. o2h Ventures was an early investor in clinical-stage UK biotechs conducting trials on 2 novel depression medicines: Neurocentrx is developing an abuse-deterrent oral ketamine pill, and Small Pharma has injectable forms of dimethyltryptamine (DMT) in Phase 2 studies.
Alongside investment activities, Jeff is interim CEO of the o2h Ventures oncology biotech Stingray Bio and advises the quantum chemistry startup Kuano. Previously Jeff was founding CEO and COO of two Cambridge UK drug discovery biotechs; he has an industry & research background across US academia, pharma, and biotech.
Alongside investment activities, Jeff is interim CEO of the o2h Ventures oncology biotech Stingray Bio and advises the quantum chemistry startup Kuano. Previously Jeff was founding CEO and COO of two Cambridge UK drug discovery biotechs; he has an industry & research background across US academia, pharma, and biotech.
Speaking In
1:45 PM - 2:45 PM
Wednesday, June 7
